Moderna MRNA Stock
Moderna Price Chart
Moderna MRNA Financial and Trading Overview
| Moderna stock price | 196.48 USD |
| Previous Close | 203.21 USD |
| Open | 202.13 USD |
| Bid | 180.21 USD x 100 |
| Ask | 196.65 USD x 100 |
| Day's Range | 186.64 - 212.19 USD |
| 52 Week Range | 22.28 - 212.19 USD |
| Volume | 18.77M USD |
| Avg. Volume | 17.15M USD |
| Market Cap | 74.84B USD |
| Beta (5Y Monthly) | 1.095 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.98 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 120.67 USD |
MRNA Valuation Measures
| Enterprise Value | 70.99B USD |
| Trailing P/E | N/A |
| Forward P/E | -42.118843 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 33.59101 |
| Price/Book (mrq) | 11.062851 |
| Enterprise Value/Revenue | 31.863 |
| Enterprise Value/EBITDA | -32.342 |
Trading Information
Moderna Stock Price History
| Beta (5Y Monthly) | 1.095 |
| 52-Week Change | 643.26% |
| S&P500 52-Week Change | 15.77% |
| 52 Week High | 212.19 USD |
| 52 Week Low | 22.28 USD |
| 50-Day Moving Average | 126.62 USD |
| 200-Day Moving Average | 69.25 USD |
MRNA Share Statistics
| Avg. Volume (3 month) | 17.15M USD |
| Avg. Daily Volume (10-Days) | 16.46M USD |
| Shares Outstanding | 399.24M |
| Float | 372.19M |
| Short Ratio | 0.99 |
| % Held by Insiders | 7.33% |
| % Held by Institutions | 80.46% |
| Shares Short | 32.87M |
| Short % of Float | 10.06% |
| Short % of Shares Outstanding | 8.22% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -141.42% |
| Operating Margin (ttm) | -557.93% |
| Gross Margin | -66.023% |
| EBITDA Margin | -98.51% |
Management Effectiveness
| Return on Assets (ttm) | -13.25% |
| Return on Equity (ttm) | -38.99% |
Income Statement
| Revenue (ttm) | 2.23B USD |
| Revenue Per Share (ttm) | 5.66 USD |
| Quarterly Revenue Growth (yoy) | 2.10% |
| Gross Profit (ttm) | -1471000064 USD |
| EBITDA | -2195000064 USD |
| Net Income Avi to Common (ttm) | -3151000064 USD |
| Diluted EPS (ttm) | -7.98 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 5.14B USD |
| Total Cash Per Share (mrq) | 12.87 USD |
| Total Debt (mrq) | 1.29B USD |
| Total Debt/Equity (mrq) | 19.04 USD |
| Current Ratio (mrq) | 2.295 |
| Book Value Per Share (mrq) | 16.945 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -1073000000 USD |
| Levered Free Cash Flow (ttm) | 299.25M USD |
Profile of Moderna
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 325 Binney Street |
| ZIP | 02142 |
| Phone | 617 714 6500 |
| Website | https://www.modernatx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 4700 |
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Q&A For Moderna Stock
What is a current MRNA stock price?
Moderna MRNA stock price today per share is 196.48 USD.
How to purchase Moderna stock?
You can buy MRNA shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Moderna?
The stock symbol or ticker of Moderna is MRNA.
Which industry does the Moderna company belong to?
The Moderna industry is Biotechnology.
How many shares does Moderna have in circulation?
The max supply of Moderna shares is 399.24M.
What is Moderna Price to Earnings Ratio (PE Ratio)?
Moderna PE Ratio is now.
What was Moderna earnings per share over the trailing 12 months (TTM)?
Moderna EPS is -7.98 USD over the trailing 12 months.
Which sector does the Moderna company belong to?
The Moderna sector is Healthcare.
Moderna MRNA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27538.69 USD — |
-0.22
|
6.46B USD — | 27341.31 USD — | 27547.2 USD — | — - | 6.46B USD — |
|
S&P 500 INDEX
SPX
US
|
7801.77 USD — |
-0.22
|
2.65B USD — | — — | — — | — - | 2.65B USD — |
|
S&P 500 (Yahoo.com)
GSPC
US
|
7801.77 USD — |
-0.22
|
2.65B USD — | 7763.34 USD — | 7807.02 USD — | — - | 2.65B USD — |
|
US100
NDX
US
|
31160.08 USD — |
-0.21
|
978.92M USD — | 30904.47 USD — | 31170.12 USD — | — - | 978.92M USD — |
|
US Tech Health Care
IXHC
US
|
1295.78 USD — |
+0.26
|
— — | 1284.67 USD — | 1308.07 USD — | — - | — — |
|
US Tech-100 After Hours Indicato
QIV
US
|
31175.24 USD — |
-0.16
|
— — | 31140.51 USD — | 31175.38 USD — | — - | — — |
|
US Tech US BuyBack Achievers Sel
DRBS
US
|
2340.09 USD — |
+0.42
|
— — | 2336.31 USD — | 2349.71 USD — | — - | — — |
|
US Tech US Smart Pharmaceuticals
NQSSPH
US
|
2160.85 USD — |
+0.62
|
— — | 2144.11 USD — | 2185.38 USD — | — - | — — |
|
US Tech US CapEx Achievers Index
CAPEXA
US
|
3856.09 USD — |
-0.32
|
— — | 3843.04 USD — | 3866.52 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
13561.68 USD — |
-0.2
|
— — | 13462.5 USD — | 13565.81 USD — | — - | — — |
|
US Tech DM Ex Japan Large Mid Ca
NQDMXJPLMAUD
US
|
2100.38 AUD 1467.26 USD |
<0.01
|
— — | 2100.38 AUD 1467.26 USD | 2100.38 AUD 1467.26 USD | — - | — — |
|
US Tech-100 ESG Net Notional Tot
NDXESG24
US
|
2549.63 EUR 2943.12 USD |
+0.46
|
— — | 2528.55 EUR 2918.79 USD | 2550.73 EUR 2944.4 USD | — - | — — |
|
US Tech-100 Equal Weighted
NDXE
US
|
10307.36 USD — |
-0.93
|
— — | 10273.09 USD — | 10331.41 USD — | — - | — — |
|
US Tech-100 Notional Net Return
XNDXNNREUR
US
|
5829.96 EUR 6729.72 USD |
+0.35
|
— — | 5786.45 EUR 6679.5 USD | 5832.17 EUR 6732.27 USD | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech-100 Micro Index
XND
US
|
311.6 USD — |
-0.21
|
— — | 309.04 USD — | 311.7 USD — | — - | — — |
|
US Tech-100 Pre Market Indicator
QMI
US
|
30968.26 USD — |
-0.82
|
— — | 30946.56 USD — | 31014.14 USD — | — - | — — |
|
US Tech-100 Reduced Value Index
NQX
US
|
6232.02 USD — |
-0.21
|
— — | 6180.89 USD — | 6234.02 USD — | — - | — — |
|
US Tech Global BuyBack Achievers
DRBG
US
|
3027.96 USD — |
-1.1
|
— — | 3025.43 USD — | 3034.86 USD — | — - | — — |
|
Stlmt ID US Tech 100
XQO
US
|
16266.86 USD — |
-0.45
|
— — | 15738.2 USD — | 16639.8 USD — | — - | — — |
- {{ link.label }} {{link}}
